Stocksigma LogoStocksigma Logo

Senores Pharmaceuticals Reports Q2FY27 IPO Proceeds Utilization and Object Revisions

CARE Ratings' monitoring report for Senores Pharmaceuticals reveals cumulative utilization of Rs. 418.83 crore from its Rs

Senores Pharmaceuticals Reports Q2FY27 IPO Proceeds Utilization and Object Revisions

Senores Pharmaceuticals Ltd 路 Others (Uncategorized) 路 29 Oct 2026, 10:48 pm

Senores Pharmaceuticals Reports Q2FY27 IPO Proceeds Utilization and Object Revisions CARE Ratings' monitoring report for Senores Pharmaceuticals reveals cumulative utilization of Rs. 418.83 crore from its Rs. 500.00 crore fresh IPO proceeds through 30th Sep'26, with Rs. 19.37 crore deployed during Q2FY27. Net unutilized proceeds of Rs. 81.17 crore remain parked primarily in bank fixed deposits. Shareholders approved revisions to issue objects via postal ballot on 4th Aug'26, reallocating funds toward subsidiary ANDA acquisitions (Rs. 15.39 crore) and plant expansions in Vadodara (Rs. 25.00 crore) and Atlanta (Rs. 24.63 crore).

Original exchange filing (PDF)

More announcements from Senores Pharmaceuticals Ltd

All Senores Pharmaceuticals Ltd announcements